再鼎医药2026 Q2产品环比收入增长11%,DLL3 ADC最快明年提交美国上市申请

智通财经
Aug 06
【再鼎医药2026 Q2产品环比收入增长11%,DLL3 ADC最快明年提交美国上市申请】再鼎医药发布2026年第二季度财报,期内公司总收入1.063亿美元,上年同期为1.1亿美元;产品收入1.058亿美元,环比增长11%;净亏损5080万美元,上年同期为4070万美元。截至6月底,公司现金及短期投资等合计7.175亿美元。公司预计年底前将有3项注册性研究开展,DLL3 ADC zoci一线小细胞肺癌数据将于10月ESMO大会公布,并计划下半年启动注册性三期研究;二线及以上小细胞肺癌关键三期预计2027年上半年完成入组,有望支持公司提交首个美国上市申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10